Avelumab and Merkel Cell Carcinoma: Evaluating Causation
From General Health Education to Targeted Exposure Analysis
For decades, public health communication has centered on general wellness principles—balanced nutrition, routine screenings, and avoidance of known carcinogens like tobacco or ultraviolet radiation. This broad foundation has served to educate populations about modifiable risk factors for various diseases, including skin cancers. Within this legacy framework, Merkel cell carcinoma (MCC) was historically discussed as a rare, aggressive neuroendocrine tumor of the skin, primarily linked to sun exposure and immunosuppression. The general health narrative emphasized prevention through sun protection and early detection, without delving into specific pharmaceutical exposures. As medical science advances, however, the scope of inquiry must expand beyond lifestyle and environmental factors to include therapeutic agents. Avelumab, a PD-L1 inhibitor approved for metastatic MCC, represents a targeted immunotherapy that modulates immune checkpoints. While its clinical benefit is established, the question of causation in the opposite direction—whether Avelumab exposure itself could contribute to MCC development—emerges as a legitimate occupational and pharmacovigilance concern. This pivot from general health education to a focused exposure-risk analysis is essential for healthcare workers, researchers, and regulators who handle or prescribe this biologic. The transition requires examining Avelumab not merely as a treatment but as a potential environmental agent in occupational settings, where chronic, low-level exposure might theoretically alter immune surveillance. Thus, the conversation shifts from population-level prevention to individual-level risk assessment in professional contexts.
Evidence-Based Assessment: Avelumab as Treatment, Not Cause
The query asks whether Avelumab causes Merkel cell carcinoma (MCC). Based on the provided evidence, Avelumab is not a cause of MCC; rather, it is an approved treatment for the disease. The evidence consistently describes Avelumab as a therapeutic agent used to treat metastatic MCC, not as a chemical trigger that induces the cancer. Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) and functions as an immune checkpoint inhibitor (https://pubmed.ncbi.nlm.nih.gov/29799096/). It was approved in the USA, EU, and Japan for the treatment of metastatic MCC, making it the first therapeutic agent specifically approved for this indication (https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the phase II JAVELIN Merkel 200 trial, where confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). This indicates that Avelumab is used to treat existing MCC, not to cause it.
Regarding adverse effects, Avelumab, like other checkpoint inhibitors, can cause immune-related adverse events (irAEs) due to overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case described hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on Avelumab, which was managed with corticosteroids, and Avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case illustrates that Avelumab can trigger immune-related complications but does not cause MCC. In terms of risk considerations, the evidence does not support a causal link between Avelumab and the development of MCC. The timeline between exposure and harm is not applicable because Avelumab is administered to patients who already have MCC. The adequacy of warnings regarding Avelumab and MCC is not directly addressed in the provided evidence, but the drug's approved indication for treating MCC implies that warnings would focus on its therapeutic use and potential adverse effects, not on causation of the disease. For affected patients, causation-related considerations are straightforward: Avelumab is a treatment for MCC, not a cause. Patients with MCC who are treated with Avelumab may experience immune-related adverse events, but these do not include the development of new MCC. The evidence does not suggest that Avelumab increases the risk of MCC or induces the cancer in any way.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
Can Avelumab cause Merkel cell carcinoma?
No, Avelumab is not a cause of Merkel cell carcinoma (MCC). It is an approved treatment for metastatic MCC. The evidence consistently shows that Avelumab is a therapeutic agent used to treat existing MCC, not a chemical trigger that induces the cancer. (https://pubmed.ncbi.nlm.nih.gov/29799096/)
What is the mechanism of action of Avelumab?
Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) and functions as an immune checkpoint inhibitor. It enhances the immune response against cancer cells and is used to treat metastatic MCC. (https://pubmed.ncbi.nlm.nih.gov/29799096/)
What are the known risk factors for Merkel cell carcinoma?
Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus. It is a rare, aggressive neuroendocrine cutaneous malignancy with increasing incidence and high rates of recurrence and mortality. (https://pubmed.ncbi.nlm.nih.gov/35877101/)
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Free Case & Eligibility Review
Individuals with documented Avelumab exposure and a related diagnosis may request an independent, no-cost eligibility review.